N
Niall M. B. Martin
Researcher at Wellcome Trust
Publications - 42
Citations - 11441
Niall M. B. Martin is an academic researcher from Wellcome Trust. The author has contributed to research in topics: Poly ADP ribose polymerase & PARP inhibitor. The author has an hindex of 27, co-authored 42 publications receiving 10001 citations. Previous affiliations of Niall M. B. Martin include Newcastle University.
Papers
More filters
Journal ArticleDOI
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer,Nuala McCabe,Christopher J. Lord,Andrew Tutt,Andrew Tutt,Damian A. Johnson,Tobias B. Richardson,Manuela Santarosa,Krystyna J. Dillon,Ian Hickson,Charlotte Knights,Niall M. B. Martin,Stephen P. Jackson,Graeme C. M. Smith,Alan Ashworth +14 more
TL;DR: BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.
Journal ArticleDOI
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.
Ian Hickson,Yan Zhao,Caroline Richardson,Sharon J. Green,Niall M. B. Martin,Alisdair I. Orr,Philip Michael Reaper,Stephen P. Jackson,Nicola J. Curtin,Graeme C. M. Smith +9 more
TL;DR: KU-55933 is a novel, specific, and potent inhibitor of the ATM kinase, which did not potentiate the cytotoxic effects of ionizing radiation on ataxia-telangiectasia cells, nor did it affect their cell cycle profile after DNA damage.
Journal ArticleDOI
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg,Janneke E. Jaspers,Ariena Kersbergen,Eline van der Burg,Anders O.H. Nygren,Serge A.L. Zander,Patrick W. B. Derksen,Michiel de Bruin,John Zevenhoven,Alan Lau,Robert Boulter,Aaron Cranston,Mark J. O'Connor,Niall M. B. Martin,Piet Borst,Jos Jonkers +15 more
TL;DR: In vivo efficacy of AZD2281 against BRCA1-deficient breast cancer is demonstrated and how GEMMs of cancer can be used for preclinical evaluation of novel therapeutics and for testing ways to overcome or circumvent therapy resistance is illustrated.
Journal ArticleDOI
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Keith Allan Menear,Claire Adcock,Robert Boulter,Xiao-Ling Fan Cockcroft,Louise Copsey,Aaron Cranston,Krystyna J. Dillon,Jan Drzewiecki,Sheila Garman,Sylvie Gomez,Hashim Javaid,Frank Kerrigan,Charlotte Knights,Alan Lau,Vincent Junior Ming-Lai Loh,Ian Timothy William Matthews,Stephen Moore,Mark J. O'Connor,Graeme C. M. Smith,Niall M. B. Martin +19 more
TL;DR: A novel series of substituted 4-benzyl-2 H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 andPARP-2 are disclosed and shows standalone activity against BRCA1-deficient breast cancer cell lines.
Journal ArticleDOI
Deubiquitylating enzymes and drug discovery: emerging opportunities.
TL;DR: This Review discusses issues and recent advances in understanding of DUB enzymology and biology as well as technological improvements that have contributed to the current interest in DUBs as therapeutic targets in diseases ranging from oncology to neurodegeneration.